MUltiple Sclerosis : T Cell / B Cell Exploration
T Cell/B Cell Collaboration in Multiple Sclerosis: Exploring an Intimate Relationship
What it found
We found no results in the registry or in papers.
This trial finished 5 years ago. We found no results in the registry or in any paper that cites it.
What it measured
Main measures
To compare the transcriptome profile of infiltrating TFH cells from CIS patients to non-MS patients with neurological inflammatory diseases
At inclusion
Immune response
Other measures (3)
To compare the transcriptome profile of infiltrating TFH cells from CIS patients to healthy volunteers.
At inclusion
Immune responseTo compare the B cell differentiation helping abilities of TFH cells from MS patients to those of HV
At inclusion
Immune responseTo compare the migration abilities of TFH cells from MS patients to those of HV
At inclusion
Who could take part
Early (CIS/RIS) · 18 and over
Show the full criteria
Inclusion criteria
Regarding MS patients (remitting or progressive untreated): * Adult (age greater than or equal to 18 years) of both sexes; * MS fulfilling the criteria of McDonald 2017; * Remittent or progressive form; * No immunomodulatory or immunosuppressive therapy for at least 3 months; * Free, informed and written consent signed by the patient. Regarding Clinically Isolated Syndrome: * Adult (age greater than or equal to 18 years) of both sexes; * Clinically isolated syndrome suggestive of MS (at least two typical lesions in two different locations); * Patient receiving a Lumbar Puncture (PL) for diagnostic purposes; * No immunomodulatory or immunosuppressive therapy for at least 3 months; * Free, informed and written consent signed by the patient. Regarding non-MS patients with neurological inflammatory disease: * Adult (age greater than or equal to 18 years) of both sexes; * Patient with non-MS neurological inflammatory disease (examples: meningitis, neurolupus, neurosarcoidosis...); * Patients with PL for diagnostic or surveillance purposes; * No immunomodulatory or immunosuppressive therapy for at least 3 months; * Free, informed and written consent signed by the patient. Regarding healthy volunteers: * Adult (age greater than or equal to 18 years) of both sexes; * Free, informed and written consent signed by the volunteer.
Exclusion criteria
Regarding all patients: * Pregnancy; * Breastfeeding; * Treatment with corticotherapy in the last month; * Patient not affiliated to health insurance; * Persons major subject to legal protection (safeguard of justice, guardianship, tutorship), persons deprived of their liberty. Regarding healthy volunteers: * Pregnancy; * Breastfeeding; * Not affiliated to social security; * Persons major subject to legal protection (safeguard of justice, guardianship, tutorship), persons deprived of their liberty.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This study, an ancillary to ABCD-SEP (NCT03744351), will be interested in more precisely characterizing circulating and infiltrating TH cells in Multiple Sclerosis whether at the transcriptomic level or at the functional level.
Loading reviews and guidelines…
Linked trials
Refers to
B Cell Differentiation in MSNot a drug-phase study · Completed
Links found where a registry record names another trial's registry number.
History
Started
Feb 2019
Main results due
Oct 2021
Finished
Oct 2021